Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women

Disease Markers

Volumn 15, Issue 4, 1999, Pages 259-267

  Erbaǧci, Ayşe Binnur ^a   Yilmaz, Necat ^a   Kutlar, Irfan ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

AFP; CA 125; CA 15 3; CA 19 9; CEA; Menstrual cycle; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; PROLACTIN; TUMOR MARKER;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CHEMOLUMINESCENCE; ENZYME IMMUNOASSAY; FEMALE; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL;

EID: 0033372202     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/960934     Document Type: Article

References (34)

1. [1] Abae, M., Gibson, M., Chapitis, J., Riddick, D.H. and Brumsted, J.R. CA-125 levels in humane uterine fluid. Fertil Steril 57, (1992) 531-534.
2. [2] Abrao, M.S., Podgaec, S., Filho, B.M., Ramos, L.O., Pinotti, J.O. and de Olivera, R.M. The use of biochemical markers in the diagnosis of pelvic endometriosis. Hum. Reprod. 12, (1997) 2523-2527.
3. [3] Aplin, J.D., Hey, N.A. and Li, T.C. MUC 1 as a cell surface and secretory component of endometrial epithelium: reduced levels in recurrent miscarriage. Am. J. Reprod. Immunol. 35, (1996) 261-266.
4. [4] Barbati, A., Cosmi, E.V., Spaziani, R., Ventura, R. and Montanino, G. Serum and peritoneal fluid CA 125 levels in patients with endometriosis. Fertil Steril 61, (1994) 438-442.
5. [5] Bennet, J.A., Semeniuk, D.J., Jacobson, H.I. and Murgita, R.A. Similarity between natural and recombinant human alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth. Breast Cancer Res. Treat. 45, (1997) 169-179.
6. [6] Bon, G.G., Kenemans, P., Dekker, J.J., Hompes, P.G., Verstraeten, R.A., van Kamp, G.J., et al. Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles, Hum. Reprod. 14, (1999) 566-570.
7. [7] Devine, P.L., McGuckin, M.A., Quin, R.J. and Ward, B.G. Serum markers CASA and CA 15-3 in ovarian cancer: all MUC 1 assays are not the same. Tumour Biol. 15, (1994) 337-344.
8. [8] Ferguson, A.T. and Davidson, N.E. Regulation of estrogen receptor alpha function in breast cancer. Crit. Rev. Oncog. 8, (1997) 29-46.
9. [9] Gendler, S.J., Spicer, A.P., Lalani, E.N., Duhig, T., Peat, N., Burchell, J., et al. Structure and biology of a carcinoma associated mucin, MUC 1. Am. Rev. Respir. Dis. 144, (1991) S42-S47.
10. [10] Hey, N.A. and Aplin, J.D. Sialyl-Lewis x and Sialyl-Lewis a are associated with MUC 1 in human. Gylcoconj. J. 13, (1996) 769-779.
11. [11] Hey, N.A., Li, T.C., Devine, P.L., Graham, R.A., Saravelos, H. and Aplin, J.D. MUC 1 in secretory phase endometrium: expression in precisely dated biopsies and flushings from normal and recurrent miscarriage patients. Hum. Reprod. 10, (1995) 2655-2662.
12. [12] Kharasch, E.D., Mautz, D., Senn, T., Lentz, G. and Cox, K. Menstrual cycle variability in midazolam pharmacokinetics. J. Clin. Pharmacol. 39, (1999) 275-280.
13. [13] Kruitwagen, R.F., Thomas, C., Poels, L.G., Koster, A.M., Willemsen, W.N. and Rolland, R. High CA-125 concentrations in peritoneal fluid of normal cyclic women with various infertility-related factors as demonstrated with two-step immunoradiometric assay. Fertil Steril 56, (1991) 863-869.
14. [14] Lalani, E.N., Berdichevsky, F., Boshell, M., Shearer, M., Wilson, D., Stauss, H., et al. Expression of the gene coding for a mucin in mouse mammary tumor cells can affect their tumorigenicity. J. Biol. Chem. 226, (1991) 15420-15426.
15. [15] Lanzone, A., Fulghesu, A.M., Guida, C., Muscetello, R., Caruso, A. and Mancuso, S. Serum CA 125 levels do not depend on ovarian steroidogenesis. Fertil Steril 54, (1990) 415-418.
16. [16] Mautsatsou, P. and Sekeris, C.E. Estrogen and progesterone receptors in the endometrium. Ann. NY Acad. Sci. 816, (1997) 99-115.
17. [17] Meisel, M., Römer, T. and Straube, W. Levels of the CASA tumor marker during the menstrual cycle. Zentralbl. Gynakol. 118, (1996) 412-413.
18. [18] Peat, N., Gendler, S.J., Lalani, N., Duhig, T. and Taylor Papadimitriou, J. Tissue specific expression of a human polimorphicepithelial mucin (MUC 1) in transgenic mice, Cancer Res. 52, (1992) 1954-1960.
19. [19] Plebani, M., Giacomini, A., Beghi, L., De Paoli, M., Roveroni, G., Galeotti, F., et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res. 16, (1996) 2249-2252.
20. [20] Price, M.R., Rye, P.D., Petrakou, E., Murray, A., Brady, K., Imai, S., et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC 1 mucin. Tumour Biol. 19(Suppl 1), (1998) 1-20.
21. [21] Rubins, J.B., Dunitz, J., Rubins, H.B., Maddaus, M.A. and Niewoehner, D.E. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J. Thorac. Cardiovasc. Surg. 116, (1998) 412-416.
22. [22] Shimizu, Y., Fujiwara, H., Akagaki, E., Hirota, K., Kono, M., Irie, T., et al. Significance of CA 125 antigen levels in patients with ovarian cancer. Gan To Kagaku Ryoho 31, (1986) 46-52.
23. [23] Soletermos, G., Nielsen, D., Schioler, V., Skovsgaard, T. and Dombernowsky, P. Tumor markers cancer antigen 15-3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin. Chem. 42, (1996) 564-575.
24. [24] Soletermos, G., Schioler, V., Nielsen, D., Skovsgaard, T. and Dombernowsky, P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin. Chem. 39, (1993) 2077-2083.
25. [25] Spitzer, M., Kaushal, N. and Benjamin, F. Maternal CA 125 levels in pregnancy and the puerperium. J. Reprod. Med. 43, (1998) 387-392.
26. [26] Stauand, B.E. and Winkel, P. Neoplasia. In: Clinical Chemistry, Theory, Analysis, Correlation. Kaplan, L.A. and Pesce, A.J. (eds.) Mosby-Year Book Inc., Missouri, (1996) 983-1003.
27. [27] Tseng, L. and Zhu, H.H. Regulation of progesterone receptor messenger ribonucleic acid by progestin in human endometrial stromal cells. Biol. Reprod. 57, (1997) 1360-1366.
28. [28] Vestergaard, E.M., Wolf, H. and Qrntoft, T.F. Increased concentrations of genotype-interpreted CA 19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium. Clin. Chem. 44, (1998) 197-204.
29. [29] Wesseling, J., van der Valk, S. and Hilkens, J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane associated mucin episialin/MUC 1. Mol. Biol. Cell 7, (1996) 565-577.
30. [30] Whitley, R.J., Meikle, W. and Wattz, N.B. Endocrinology Part 6. In: Tietz Fundementals of Clinical Chemistry. Burtis, C.A. and Ashwood, E.R. (eds.) WB Saunders Co, USA, (1996) 671-684.
31. [31] Yilmaz, N., Aynacioǧlu, Ş., Erbaǧci, A.B., Cascorbi, I. and Roots, I. Implication of arylamine N-acetyltransferase (NAT 2) polymorphsim on levels of tumour markers CEA, AFP, CA 125, CA 19.9, CA 15.3. Biomarkers 4, (1999) 129-134.
32. [32] Zeimet, A.G., Muller-Holzner, E., Marth, C., Daxenbichler, G. and Dapunt, O. Tumor marker CA 125 in tissues of the female reproductive tract and in serum during normal menstrual cycle. Fertil. Steril. 59, (1993) 1028-1035.
33. [33] Zarghami, N., Grass, L., Sauter, E.R. and Diamandis, E.P. Prostate specific antigen in serum during the menstrual cycle. Clin. Chem. 43, (1997) 1862-1868.
34. [34] Zweers, A., De Boever, J., Serreyn, R. and Vandekerckhove, D. Correlation between peripheral CA-125 and ovarian activity. Fertil. Steril. 53, (1990) 409-414.